SAFETY AND EFFICACY OF LOSARTAN ON DIALYSIS DEPENDANT CHRONIC KIDNEY DISEASE PATIENTS- AN INDIAN RANDOMISED CONTROLLED TRIAL

EFFICACY AND SAFETY OF LOSARTAN ON REGRESSION OF LEFT VENTRICULAR HYPERTROPHY AND IMPROVEMENT IN CARDIAC FUNCTION IN HYPERTENSIVE CHRONIC KIDNEY DISEASE PATIENTS ON HAEMODIALYSIS

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2019/01/017342

Enrollment

Registered

2019-01-31

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N11- Chronic tubulo-interstitial nephritis

Interventions

Intervention1: LOSARTAN 25 MG ONCE DAILY POST DIALYSIS ORALLY FOR 1 WEEK AFTER THAT IF TOLERATED DOSE INCREASED TO 50 MG ONCE DAILY FOR 6 MONTHS: LOSARTAN IS AN ANTI HYPERTENSIVE DRUG THAT USED IN CHR

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patient of age within 18-60 year. 2. CKD stage 5 on haemodialysis. 3. On maintenance haemodialysis 3 per week. 4. A-V Fistula is used as haemodialysis access. 5. Haemoglobin level > 10gm%. 6. Echo-cardiographic evidence of Left ventricular hypertrophy. 7. Pre dialysis BP > 140/90 on 2 occassions. 8. No contraindication to any of the medication used in the study.

Exclusion criteria

Exclusion criteria: 1. Life expectancy less than 6 months. 2. Pregnancy and unwilling to take contraception. 3. Patients with active infection. 4. Past history of allergy or side effects to losartan. 5. Contraindication to start losartan. 6. Unwilling to give consent.

Design outcomes

Primary

Measure	Time frame
A. The primary outcome will be the percentage of objective improvement of echo-cardiographic parameters after the study period .Timepoint: 6 MONTHS	—

Secondary

Measure	Time frame
a) Mortality during study period. b) Adverse effects (hyperkalaemia, hypotension, anaemia, transaminitis, allergic reaction). c) Hospital admission due to heart failure d) Hypertension requiring more anti-hypertensives. Timepoint: 6 MONTHS	—

Countries

India

Contacts

Public ContactSWASTIK PURKAIT

INSTITUTE OF POST GRADUATE MEDICAL EDUCATION AND RESEARCH

swastikpurkait@gmail.com09433848257

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026